Author Archives: Simon
First patient treated in Cutaneous Melanoma patient with secondary resistance
Today marks a major milestone for MonTa Biosciences: the first patient has been dosed in [...]
Meet us at BioEquity in Praha in early May
MonTa Biosciences will be joining the BioEquity meeting in Praha in early May to build [...]
MonTa Biosciences Initiates Expansion Phase with Systemic TLR7 Agonist MBS8 in Checkpoint-Resistant Melanoma Amid Renewed Momentum in the TLR7 Field
Please find our Press Release here: Press Release Feb 2026 MonTa initiates expansion clinical study
MonTa Biosciences announce submission of clinical protocol for expansion phase
MonTa Biosciences announces submission of clinical protocol to expand treatment of our second generation TLR7 [...]
Innate Immune Activation nearly Doubles Survival combined with Checkpoint Therapy
In a landmark retrospective study published in Nature by Grippin et al. (2025), researchers at [...]
MonTa announces completion of phase I does-escalation
MonTa announces completion of our phase I dose-escalation study with completion of the last cohort [...]
MonTa Biosciences Granted Broad U.S. Patent for Lead Immunotherapy Drug MBS8
We are pleased to announce that MonTa Biosciences has been granted a key U.S. patent [...]
MBS8 preclinical data published in prestigious Journal of Immunology
MonTa shares publication of MBS8 and how our TLR7 agonist demonstrates superior anti tumor activity [...]
MonTa Biosciences Secures Key Patents in Israel, China, and Japan for MBS8
We are proud to announce that MonTa Biosciences has been granted patents in Israel, China, [...]